| Flexibility for your patients’ busy lifestyles. |
View online |
|
|
|
|
| Esperoct® is indicated for on-demand treatment and control of bleeding episodes, perioperative bleed management, and routine prophylaxis in adults and children with hemophilia A. |
| See limitations of use below. |
|
|
|
| Sign up to stay up to date on the latest bleeding disorders news from novoMEDLINK™ |
|
| |
| Flexibility and protection on the go1,a |
|
|
|
 |
|
| Esperoct® offers the flexibility your hemophilia A patients deserve:1-5,a |
| • |
protection for all ages, from pediatric to adult |
| • |
compact packaging |
| • |
the broadest EHL treatment temperature stability1-5,a |
| • |
individualized dosing frequency for bleeding episodes |
|
| Get to know Esperoct®—a flexibility factor1,a |
| aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 |
| See Prescribing Information for complete product storage information. |
|
| Selected Important Safety Information |
| Contraindications |
| |
• |
Do not use in patients who have known hypersensitivity to Esperoct® or its
components, including hamster proteins
|
|
|
Warnings and Precautions
|
| |
• |
Hypersensitivity reactions, including anaphylaxis, may occur. Should
hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate
treatment
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
| Discover personalized professional education on novoMEDLINK™. |
 |
| If you found this information useful and would like to receive more curated educational updates and product information, create your account on novoMEDLINK™. |
|
|
|
|
| Indications and Usage |
|
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated
for use in adults and children with hemophilia A for on-demand treatment and control of bleeding
episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency
of bleeding episodes
|
| |
• |
Esperoct® is not indicated for the treatment of von Willebrand
disease
|
|
|
Important Safety Information (cont’d)
|
| Warnings and Precautions (cont’d) |
| |
• |
Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay
that measures Factor VIII inhibitor concentration if bleeding is not controlled with
the recommended dose of Esperoct® or if the expected plasma Factor
VIII activity levels are not attained
|
|
| Adverse Reactions |
| |
• |
The most frequently reported adverse reactions in clinical trials (≥1%) were
rash, redness, itching (pruritus), and injection site reactions
|
|
| Please click here for Prescribing Information. |
|
|
References:
| 1. |
Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2022. |
| 2. |
Eloctate® [package insert]. Bioverativ Therapeutics Inc.; 2023. |
| 3. |
Adynovate® [package insert]. Lexington, MA: Baxalta US Inc.; 2023. |
| 4. |
Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018. |
| 5. |
Altuviiio™ [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.; 2023 |
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2023 Novo Nordisk All rights reserved. US23ESP00012 September 2023 |
 |
|
|
|